FLEX Trial of Chemo with or without Erbitux in First Line NSCLC Data Available

---

May 31, 2008 - 8:49 pm email to a friend printer friendly view / write comments

(0 votes, average: 0 out of 5)
You need to be a registered member to rate this post.

 Loading ...

Dr. West

   There’s a single lung cancer trial being presented 6/1/08 at ASCO’s Plenary Session, at which the most important cancer studies of the year are presented.  This is on the FLEX trial that I described in a prior post, and which was already reported to be positive, at a press release all the way back in September of last year.  We’ll actually see the full data at the presentation, but the abstract just became publically available (here) and provides some additional information. 

    Some financial analysts have already described the findings and potential financial implications (here), but I’ll give you an oncologist’s perspective, and a sense of what my colleagues feel about the strength or weakness of the results and what they’ll mean to the changing standards for lung cancer treatment, after the session Sunday.

Posted in: General                     email to a friend printer friendly